End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
124 MXN | -2.36% | -.--% | -2.36% |
Sales 2024 * | 39.35M 655M 3.09B | Sales 2025 * | 58.17M 968M 4.57B | Capitalization | 70.86M 1.18B 5.57B |
---|---|---|---|---|---|
Net income 2024 * | -120M -2B -9.43B | Net income 2025 * | -77M -1.28B -6.05B | EV / Sales 2024 * | -1.44 x |
Net cash position 2024 * | 127M 2.12B 10.02B | Net cash position 2025 * | 54.53M 907M 4.29B | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
-0.65
x | P/E ratio 2025 * |
-1.24
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | -2.36% | ||
3 months | -2.36% | ||
6 months | -4.62% | ||
Current year | -2.36% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 04/09/18 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 11/04/21 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 05/11/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 30/11/08 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 04/09/18 |
Elan Ezickson
BRD | Director/Board Member | 60 | 11/12/19 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+34.69% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.21% | 244B | |
+9.99% | 208B | |
-4.13% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- MRNS Stock
- MRNS * Stock